TelyRx Expands Women's Health Offerings with New Menopause Supplement
TelyRx Holdings (TELYF) is expanding its menopause offerings through a partnership with SISTERLY to offer the women's health brand's supplement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TelyRx Holdings (TELYF) is expanding its menopause offerings through a partnership with SISTERLY to offer the women's health brand's supplement.
The partnership launches in October 2026. TelyRx will become SISTERLY's first U.S. pharmacy partner to offer The Elevator, a daily multivitamin containing 23 nutrients in a powder sachet. The supplement will sit alongside TelyRx's existing prescription menopause treatments, broadening the options available for women navigating perimenopause and menopause.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Partnership with women's health company SISTERLY broadens the options available alongside prescription treatments for women navigating perimenopause and menopause
"Women deserve more choices when it comes to menopause," said Vanessa Slowey, President and Chief Executive Officer of TelyRx. "Every woman's experience is different, and what works for one may not work for another. We're building a holistic women's health offering around that reality, making it easier for women to access a broad range of options and decide what works best for them."
Through the partnership, TelyRx will become the first
"Partnering with TelyRx allows us to bring The Elevator to more women in the
The partnership launches in October during World Menopause Month, as TelyRx continues to broaden the range of options available to women dealing with perimenopause and menopause symptoms.
TelyRx has spent years building the infrastructure behind a simpler prescription experience, connecting independent clinical review by Board-certified providers with fulfillment by licensed
Learn more about The Elevator and TelyRx's menopause support offerings at TelyRx.com. Browse more than 500 medications and order in minutes.
About TelyRx
TelyRx is an integrated digital healthcare platform that makes everyday prescription medications easier to access. Patients connect with independent, state-licensed healthcare providers who evaluate their needs and prescribe treatment when appropriate. Prescriptions are filled by TelyRx's licensed pharmacies and delivered directly to patients' doors. Serving patients across 48 U.S. states and all territories, TelyRx provides access to more than 500 common, FDA-approved medications for over 60 common health conditions through a seamless, convenient experience.
About SISTERLY
SISTERLY is an Irish female-founded nutrition company on a mission to raise standards in women's health through premium, science-led supplementation. Founded by three women who recognised the need for a more considered approach to female nutrition, SISTERLY brings together leading doctors, scientists, dieticians and women's health experts to develop formulations tailored specifically to women's physiology.
Its multi-award-winning supplement, The Elevator, combines 23 female-focused nutrients in one convenient powder sachet, supporting energy, immunity, normal hormonal function and healthy skin and hair. With a commitment to ingredient quality, scientific expertise and female nutritional needs, SISTERLY is helping women take a more informed, proactive approach to their wellbeing at every life stage, including perimenopause and menopause.
Forward-Looking Statements
This press release includes certain statements that may be deemed "forward-looking statements," including, but not limited to, statements regarding the patients' needs and demands, the potential for the new platform to provide patients with easier and faster access, transparency, delivery tracking and decreased complexity, the growth in our returning customer base and the future of the category. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include, but are not limited to, technology issues, delays, implementation problems, and the risks described under "Risk Factors" in the Company's Management Discussion and Analysis dated May 12, 2026, filed on SEDAR+. Although the Company believes the expectations reflected in these forward-looking statements are reasonable, there can be no assurance that they will prove to be accurate. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, the Company undertakes no obligation to update any forward-looking statements.
Media Contact
Havas Red
TelyRxPress@havasred.com
Investor Relations Contact
Neil Weber
Investor Relations
(647) 222-0574
investors@telyrx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/telyrx-expands-womens-health-offerings-with-new-menopause-supplement-302900666.html
SOURCE TelyRx Holdings Inc.